+91
By proceeding, you agree to all T&C*
Didn't receive the code? Resend
AGARWALEYE

Dr. Agarwals Health Care Share Price

₹523.50 +10.7 (2.09%)
30.55% Gain from 52W Low

04 Nov, 2026 3:31 PM (IST)

Dr. Agarwals Health Care live price: ₹523.50. It opened at ₹509 vs previous close ₹513; intraday high/low: ₹529/₹509. The 50 & 200 DMA stand at ₹490.40/₹476.90.

Dr. Agarwals Health Care Performance

  • Today's Low
  • ₹509
  • Today's High
  • ₹529
  • 52 Week Low
  • ₹401
  • 52 Week High
  • ₹568
  • Open Price₹509
  • Previous Close₹513
  • Volume262,477
  • 50 DMA₹490.40
  • 100 DMA₹487.20
  • 200 DMA₹476.90

Dr. Agarwals Health Care Chart

Investment Returns

  • Over 1 Month + 7.62%
  • Over 3 Month + 8.32%
  • Over 6 Month + 17.61%
  • Over 1 Year + 0.94%

Smart Investing Starts Here Start SIP with Dr. Agarwals Health Care for Steady Growth!

Invest Now

Dr. Agarwals Health Care Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 111.9
  • PEG Ratio
  • 2.4
  • Market Cap Cr
  • 16,596
  • P/B Ratio
  • 8
  • Average True Range
  • 17.3
  • EPS
  • 4.7
  • Dividend Yield
  • 0
  • MACD Signal
  • 5.5
  • RSI
  • 70.67
  • MFI
  • 88.03

Latest Stock News Updates

Dr. Agarwals Health Care Ltd - 544350 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

Intimation of Analyst / Earnings Conference call to discuss the Unaudited Financial Results (Standalone & Consolidated) of the Company for the Quarter and Half-Year ended September 30, 2026, is attached.

Dr. Agarwals Health Care Ltd - 544350 - Board Meeting Intimation for Consideration And Approval Of The Unaudited Financial Results (Standalone And Consolidated) Of The Company For The Quarter And Half Year Ended September 30, 2026

Dr. Agarwals Health Care Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/11/2026 ,inter alia, to consider and approve the Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter and half year ended September 30, 2026

Dr. Agarwals Health Care Ltd - 544350 - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

Allotment of 18,200 Equity Shares pursuant to the exercise of options granted under Dr. Agarwal''s Health Care Limited - Employees Stock Option Scheme 2022

Dr. Agarwals Health Care Financials

Dr. Agarwals Health Care Technicals

EMA & SMA

Current Price
₹523.50
+ 10.7 (2.09%)
pointer
  • Bearish Moving Average 0
  • Bullish Moving Average 16
  • 20 Day
  • ₹491.00
  • 50 Day
  • ₹490.40
  • 100 Day
  • ₹487.20
  • 200 Day
  • ₹476.90

Resistance and Support

520.63 Pivot Speed
  • R3 552.60
  • R2 541.00
  • R1 532.20
  • S1 511.90
  • S2 500.30
  • S3 491.50

Dr. Agarwals Health Care Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-11-05 Quarterly Results
2026-08-04 Quarterly Results
2026-05-21 Audited Results
2026-02-03 Quarterly Results
2025-10-30 Quarterly Results

Dr. Agarwals Health Care Shareholding Pattern

49.56%
32.33%
14.18%
2.23%
1.68%

About Dr. Agarwals Health Care

Dr Agarwal's Health Care is primarily engaged in running, owning and managing eye care hospitals, opticals, pharmacies, etc. and related services. View More
  • NSE Symbol
  • AGARWALEYE
  • BSE Symbol
  • 544350
  • ISIN
  • INE943P01029

Similar Stocks to Dr. Agarwals Health Care

Dr. Agarwals Health Care FAQs

Dr. Agarwals Health Care share price is ₹523 As on 05 November, 2026 | 06:04

The Market Cap of Dr. Agarwals Health Care is ₹16596.3 Cr As on 05 November, 2026 | 06:04

The P/E ratio of Dr. Agarwals Health Care is 111.9 As on 05 November, 2026 | 06:04

The PB ratio of Dr. Agarwals Health Care is 8 As on 05 November, 2026 | 06:04

The 52 week High & Low of Dr. Agarwals Health Care is ₹567.8/₹401 respectively As on 05 November, 2026 | 06:04

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23